The LPA gene C93T polymorphism influences plasma lipoprotein(a) levels and is independently associated with susceptibility to peripheral arterial disease

Simple item page
dc.contributor.authorCatalano, Mariella
dc.contributor.authorCortelazzo, Adriano
dc.contributor.authorCarzaniga, Gianni
dc.contributor.authorPerilli, Edoardo
dc.contributor.authorEmanuele, Enzo
dc.contributor.buuauthorYılmaz, Yusuf
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0003-4518-5283tr_TR
dc.contributor.researcheridK-6651-2012tr_TR
dc.contributor.scopusid22936014300tr_TR
dc.date.accessioned2024-04-05T05:52:57Z
dc.date.available2024-04-05T05:52:57Z
dc.date.issued2007-09-21
dc.description.abstractBackground: Plasma lipoprotein(a) [Lp(a)] levels are mainly genetically determined. The C93T polymorphism is a naturally occurring variant of the LPA gene that may influence Lp(a) concentration. The role of Lp(a) in the pathogenesis of peripheral arterial disease (PAD) has not been firmly established.Methods: A total of 299 patients with PAD and 312 PAD-free control subjects were investigated. Genotyping of the LPA C93T polymorphism was performed by means of PCR-RFLPs. Plasma Lp(a) levels were determined by ELISA.Results: Subjects carrying at least one LPA 93T allele had lower Lp(a) levels. The prevalence rate of the 93T allele was significantly higher in control subjects (19.5%) than in PAD patients (13.0%, P=0.012). In multivariate logistic regression analysis with covariates including traditional risk factors, the 93T allele was independently associated with a reduced risk of PAD (OR=0.75, 95% CI=0.51-0.95, P=0.031).Conclusion: The 93T allele of the LPA gene is associated with a reduced risk of PAD and low Lp(a) levels.en_US
dc.identifier.citationCatalano, M. vd. (2008). "The LPA gene C93T polymorphism influences plasma lipoprotein(a) levels and is independently associated with susceptibility to peripheral arterial disease". Clinica Chimica Acta, 387(1-2), 109-112.en_US
dc.identifier.doihttps://doi.org/10.1016/j.cca.2007.09.014
dc.identifier.eissn1873-3492
dc.identifier.endpage112tr_TR
dc.identifier.issn0009-8981
dc.identifier.issue1-2tr_TR
dc.identifier.pubmed17942087tr_TR
dc.identifier.scopus2-s2.0-35748985282tr_TR
dc.identifier.startpage109tr_TR
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0009898107004822en_US
dc.identifier.urihttps://hdl.handle.net/11452/41047
dc.identifier.volume387tr_TR
dc.identifier.wos000251475900019tr_TR
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.collaborationYurt dışıtr_TR
dc.relation.journalClinica Chimica Actaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAtherosclerosisen_US
dc.subjectLipoprotein(a)en_US
dc.subjectPeripheral arterial diseaseen_US
dc.subjectPolymorphismen_US
dc.subjectApolipoprotein(a) geneen_US
dc.subjectSerum lipoprotein(a)en_US
dc.subjectLp(a) concentrationsen_US
dc.subjectRisk-factorsen_US
dc.subjectAtherosclerosisen_US
dc.subjectMetaanalysisen_US
dc.subjectAfricansen_US
dc.subjectStrokeen_US
dc.subjectImpacten_US
dc.subjectSizeen_US
dc.subjectMedical laboratory technologyen_US
dc.subject.emtreeC reactive proteinen_US
dc.subject.emtreeCholesterolen_US
dc.subject.emtreeCreatinineen_US
dc.subject.emtreeGenomic DNAen_US
dc.subject.emtreeLipoprotein Aen_US
dc.subject.emtreeTriacylglycerolen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeAlleleen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeAtherosclerosisen_US
dc.subject.emtreeBody massen_US
dc.subject.emtreeCholesterol blood levelen_US
dc.subject.emtreeCigarette smokingen_US
dc.subject.emtreeCcontrolled studyen_US
dc.subject.emtreeCreatinine blood levelen_US
dc.subject.emtreeEnzyme linked immunosorbent assayen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGene frequencyen_US
dc.subject.emtreeGenetic polymorphismen_US
dc.subject.emtreeGenotypeen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHypertensionen_US
dc.subject.emtreeLipoprotein blood levelen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNon insulin dependent diabetes mellitusen_US
dc.subject.emtreePeripheral occlusive artery diseaseen_US
dc.subject.emtreePeripheral vascular diseaseen_US
dc.subject.emtreePolymerase chain reactionen_US
dc.subject.emtreePrevalenceen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeRestriction fragment length polymorphismen_US
dc.subject.emtreeRisk assessmenten_US
dc.subject.emtreeRisk factoren_US
dc.subject.meshAgeden_US
dc.subject.meshFemaleen_US
dc.subject.meshGenetic predisposition to diseaseen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshPeripheral vascular diseasesen_US
dc.subject.meshPolymerase chain reactionen_US
dc.subject.meshPolymorphism, geneticen_US
dc.subject.meshPolymorphismen_US
dc.subject.meshRestriction fragment lengthen_US
dc.subject.scopusLipoprotein A; Blood Component Removal; Proprotein Convertase 9en_US
dc.subject.wosMedical laboratory technologyen_US
dc.titleThe LPA gene C93T polymorphism influences plasma lipoprotein(a) levels and is independently associated with susceptibility to peripheral arterial diseaseen_US
dc.typeArticleen_US
dc.wos.quartileQ1 (Medical laboratory technology)en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science